Muenchen Klinik gGmbH — Clinical Trial Site

65 Registered trials

29 Currently recruiting

Organisation

Muenchen Klinik gGmbH

Location

Munich, Germany

Identifier

ORG-100019127

Address

Sanatoriumsplatz 2, Untergiesing-Harlaching, 81545, Germany

Departments

Clinic for Pneumology and Pneumological Oncology
Department of gastroenterology and gastroenterologic oncology
Frauenklinik
Gastroenterologie und gastroenterologische Onkologie
Gastroenterologie, Hepatologie und Gastroenterologische Onkologie
Hematology and Oncology
Innere Medizin und Hämatologie und Onkologie
Interdisziplinäre Onkologische Tagesklinik
Kinder-Hämatologie und -onkologie
Kinderklinik Päd. Hämatologie und Onkologie
Klinik fuer Haematologie und Onkologie
Klinik fuer Onkologie und Haematologie
Klinik fuer Pneumologie und Pneumologische Onkologie
Klinik für Gastroenterologie und gastroenterologische Onkologie
Klinik für Gastroenterologie, Hepatologie und Gastroenterologische Onkologie
Klinik für Hämatologie und Onkologie
Klinik für Hämatologie und Onkologie, Studienbüro Neuperlach / Harlaching
Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin
Klinik für Onkologie und Hämatologie
Klinik für Pleumologie und Onkologischen Pneumologie
Klinik für Pneumologie und Pneumologische Onkologie
Klinikum Bogenhausen Klinik für Pneumologie und Pneumologiesche Onkologie
Klinikum Bogenhausen, Klinik f. Pneumologie u. Onkologie
München Klinik Bogenhausen Klinik für Pneumologie und Pneumologische Onkologie
München Klinik Neuperlach
München Klinik Neuperlach Klinik für Hämatologie und Onkologie
München Klinik Neuperlach Tumorzentrum Süd Klinik für Hämatologie u. Onkologie
München Klinik Neuperlach, Klinik fuer Haematologie und Onkologie
München Klinik Neuperlach, Klinik für Hämatologie und Onkologie
Oncology and visceral oncology center
Onkologie und Hämatologie
Onkologische Tagklinik
Paedriatrics, Department of Oncology and Hematology
Pneumologie und Pneumologische Onkologie
Pneumologische Onkologie
Pulmonology

Clinical trials at this site (65)

Search interface

Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inh… Not authorised

2023-505311-20-00 Metastatic Non-Small Cell Lung Cancer 5
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum… Pending

2025-521209-42-00 advanced colorectal cancer with wild-type RAS and right 6
Use of the chemotherapy FOLFIRI and cetuximab if given with treatment breaks or continuously in patients with newly diagnosed metastatic col… Pending

2025-522377-12-00 metastatic colorectal cancer 5
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell L… Pending

2025-522818-23-00 Small Cell Lung Cancer (SCLC) 5
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat… Pending

2025-523735-19-00 Metastatic Microsatellite Stable Colorectal Cancer 5
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorect… Recruiting

2025-523521-18-00 Metastatic Colorectal Cancer 5 2026-06-09
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced … Recruiting

2023-503221-19-00 Advanced Non-Small Cell Lung Cancer 4 2024-04-18
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy… Recruiting

2025-523085-24-00 Biliary Tract Cancer 5 2026-04-13
Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met… Recruiting

2025-523224-45-00 Untreated, Unresectable or Metastatic Colorectal Cancer 10 2026-03-30
Visugromab in Cachexia International Trial Recruiting

2025-523533-25-00 Cancer-associated Cachexia 10 2026-03-26
Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc… Recruiting

2024-515765-34-00 English First-line extensive-stage small-cell lung canc 5 2026-02-04
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i… Recruiting

2024-518365-10-00 Previously Untreated Advanced or Metastatic Non-Squamou 5 2025-10-28
Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting

2025-520672-26-00 Gastrointestinal Neoplasms 9 2025-09-16
Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting

2024-518154-16-00 non-small cell lung cancer 5 2025-08-27
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
A Phase 1b/2 study of arfolitixorin as part of 5-fluorouracil-based treatment regimens in the first-line treatment of metastatic colorectal … Recruiting

2024-516802-43-00 metastatic colorectal cancer 9 2025-04-09
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
PRESERVE-003: ONC-392 (Study Drug) Versus Docetaxel (Standard of Care) in Metastatic Non-small Cell Lung Cancer That Progressed on PD-1/PD-L… Recruiting

2023-505311-20-01 Metastatic Non-Small Cell Lung Cancer 5 2025-03-21
A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-515008-38-00 Metastatic Non-squamous Non-small Cell Lung Cancer Whos 5 2025-02-14
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28
A trial to learn how safe Dato-DXd is when given with osimertinib, and how well it works compared to osimertinib alone in people who have ad… Recruiting

2023-509883-89-00 Epidermal growth factor receptor (EGFR) mutation-positi 5 2025-01-09